Related Experiment Video
Updated: Jun 8, 2026
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Moyamoya disease: recent progress and outlook.
Jun C Takahashi1, Susumu Miyamoto
1Department of Neurosurgery, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Kyoto, Japan. juntak@kuhp.kyoto-u.ac.jp
Neurologia Medico-Chirurgica
|October 2, 2010
Summary
Moyamoya disease research continues to address its causes and treatments for stroke. Ongoing studies aim to clarify epidemiology, genetics, and prevent recurrent hemorrhagic events.
Area of Science:
- Neurology
- Vascular Biology
- Genetics
Background:
- Moyamoya disease, a condition known for over 40 years, is characterized by progressive stenosis of the internal carotid arteries and the circle of Willis.
- It leads to ischemic and hemorrhagic strokes due to abnormal blood vessel development.
Purpose of the Study:
- To review recent advancements in understanding Moyamoya disease.
- To discuss current therapeutic strategies for managing associated strokes.
- To identify unresolved challenges and future research directions.
Main Methods:
- Literature review of recent studies on Moyamoya disease.
- Analysis of current treatment outcomes for stroke prevention and management.
- Discussion of epidemiological, genetic, and clinical challenges.
Main Results:
- Significant progress has been made in understanding the vasculopathy underlying Moyamoya disease.
- Therapeutic interventions have improved outcomes for ischemic stroke, but hemorrhagic events remain a concern.
- Key areas requiring further investigation include precise epidemiology and genetic factors.
Conclusions:
- Despite advances, critical questions regarding Moyamoya disease epidemiology, genetic mechanisms, and prevention of recurrent hemorrhages persist.
- Continued research is essential for comprehensive management and improved patient outcomes.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...